Cargando…
Eliminating microscopic lymph node metastasis by performing pelvic lymph node dissection during radical prostatectomy for prostate cancer
The oncological benefit of pelvic lymph node dissection (PLND) for prostate cancer (PCa) remains unclear. The therapeutic effect of PLND on the elimination of microscopic metastases during radical prostatectomy (RP) for PCa was examined in the current study. A total of 348 Japanese patients with hig...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
D.A. Spandidos
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6951226/ https://www.ncbi.nlm.nih.gov/pubmed/31929879 http://dx.doi.org/10.3892/mco.2019.1965 |
_version_ | 1783486244718641152 |
---|---|
author | Furubayashi, Nobuki Negishi, Takahito Uozumi, Tomoharu Shiraishi, Kouichi Taguchi, Kenichi Shimokawa, Mototsugu Nakamura, Motonobu |
author_facet | Furubayashi, Nobuki Negishi, Takahito Uozumi, Tomoharu Shiraishi, Kouichi Taguchi, Kenichi Shimokawa, Mototsugu Nakamura, Motonobu |
author_sort | Furubayashi, Nobuki |
collection | PubMed |
description | The oncological benefit of pelvic lymph node dissection (PLND) for prostate cancer (PCa) remains unclear. The therapeutic effect of PLND on the elimination of microscopic metastases during radical prostatectomy (RP) for PCa was examined in the current study. A total of 348 Japanese patients with high- or intermediate-risk PCa without lymph node metastasis, who underwent antegrade RP at the Kyushu Cancer Center (Fukuoka, Japan) between August 1998 and May 2013 were retrospectively analyzed. The patients were divided into the standard (obturator + internal iliac nodes) group and the expanded (standard + additional nodes) group according to the extent of PLND. Preoperative and postoperative characteristics were also analyzed to determine the factors associated with prostate-specific antigen (PSA) failure. Standard and expanded PLND were performed in 70.9% (247/348) and 29.1% (101/348) of cases, respectively. The results revealed that preoperative PSA levels were the only marked difference between the two groups. No differences were observed in the other preoperative and postoperative characteristics. Furthermore, the rate of PSA recurrence in each group did not differ to a statistically significant extent (P=0.3622). Reducing the area of dissection from expanded PLND to standard PLND significantly reduced the number of dissected lymph nodes (P<0.0001). Additionally, the PSA level, clinical tumor stage, Gleason score of the biopsy specimen, pathological tumor stage and extent of PLND were all associated with PSA recurrence, as determined via multivariate Cox hazards regression analysis (P=0.0177, P=0.0023, P=0.0027, P<0.0001 and P=0.0164, respectively). In high- and intermediate-risk patients without lymph node metastasis, a greater number of lymph nodes were dissected when the extent of dissection was greater. Furthermore, the extent of PLND was a significantly associated with PSA failure. The results indicated that PLND exerted a therapeutic effect by eliminating microscopic pelvic lymph node metastases that were not detected by routine pathological examinations. |
format | Online Article Text |
id | pubmed-6951226 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | D.A. Spandidos |
record_format | MEDLINE/PubMed |
spelling | pubmed-69512262020-01-11 Eliminating microscopic lymph node metastasis by performing pelvic lymph node dissection during radical prostatectomy for prostate cancer Furubayashi, Nobuki Negishi, Takahito Uozumi, Tomoharu Shiraishi, Kouichi Taguchi, Kenichi Shimokawa, Mototsugu Nakamura, Motonobu Mol Clin Oncol Articles The oncological benefit of pelvic lymph node dissection (PLND) for prostate cancer (PCa) remains unclear. The therapeutic effect of PLND on the elimination of microscopic metastases during radical prostatectomy (RP) for PCa was examined in the current study. A total of 348 Japanese patients with high- or intermediate-risk PCa without lymph node metastasis, who underwent antegrade RP at the Kyushu Cancer Center (Fukuoka, Japan) between August 1998 and May 2013 were retrospectively analyzed. The patients were divided into the standard (obturator + internal iliac nodes) group and the expanded (standard + additional nodes) group according to the extent of PLND. Preoperative and postoperative characteristics were also analyzed to determine the factors associated with prostate-specific antigen (PSA) failure. Standard and expanded PLND were performed in 70.9% (247/348) and 29.1% (101/348) of cases, respectively. The results revealed that preoperative PSA levels were the only marked difference between the two groups. No differences were observed in the other preoperative and postoperative characteristics. Furthermore, the rate of PSA recurrence in each group did not differ to a statistically significant extent (P=0.3622). Reducing the area of dissection from expanded PLND to standard PLND significantly reduced the number of dissected lymph nodes (P<0.0001). Additionally, the PSA level, clinical tumor stage, Gleason score of the biopsy specimen, pathological tumor stage and extent of PLND were all associated with PSA recurrence, as determined via multivariate Cox hazards regression analysis (P=0.0177, P=0.0023, P=0.0027, P<0.0001 and P=0.0164, respectively). In high- and intermediate-risk patients without lymph node metastasis, a greater number of lymph nodes were dissected when the extent of dissection was greater. Furthermore, the extent of PLND was a significantly associated with PSA failure. The results indicated that PLND exerted a therapeutic effect by eliminating microscopic pelvic lymph node metastases that were not detected by routine pathological examinations. D.A. Spandidos 2020-02 2019-12-13 /pmc/articles/PMC6951226/ /pubmed/31929879 http://dx.doi.org/10.3892/mco.2019.1965 Text en Copyright: © Furubayashi et al. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made. |
spellingShingle | Articles Furubayashi, Nobuki Negishi, Takahito Uozumi, Tomoharu Shiraishi, Kouichi Taguchi, Kenichi Shimokawa, Mototsugu Nakamura, Motonobu Eliminating microscopic lymph node metastasis by performing pelvic lymph node dissection during radical prostatectomy for prostate cancer |
title | Eliminating microscopic lymph node metastasis by performing pelvic lymph node dissection during radical prostatectomy for prostate cancer |
title_full | Eliminating microscopic lymph node metastasis by performing pelvic lymph node dissection during radical prostatectomy for prostate cancer |
title_fullStr | Eliminating microscopic lymph node metastasis by performing pelvic lymph node dissection during radical prostatectomy for prostate cancer |
title_full_unstemmed | Eliminating microscopic lymph node metastasis by performing pelvic lymph node dissection during radical prostatectomy for prostate cancer |
title_short | Eliminating microscopic lymph node metastasis by performing pelvic lymph node dissection during radical prostatectomy for prostate cancer |
title_sort | eliminating microscopic lymph node metastasis by performing pelvic lymph node dissection during radical prostatectomy for prostate cancer |
topic | Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6951226/ https://www.ncbi.nlm.nih.gov/pubmed/31929879 http://dx.doi.org/10.3892/mco.2019.1965 |
work_keys_str_mv | AT furubayashinobuki eliminatingmicroscopiclymphnodemetastasisbyperformingpelviclymphnodedissectionduringradicalprostatectomyforprostatecancer AT negishitakahito eliminatingmicroscopiclymphnodemetastasisbyperformingpelviclymphnodedissectionduringradicalprostatectomyforprostatecancer AT uozumitomoharu eliminatingmicroscopiclymphnodemetastasisbyperformingpelviclymphnodedissectionduringradicalprostatectomyforprostatecancer AT shiraishikouichi eliminatingmicroscopiclymphnodemetastasisbyperformingpelviclymphnodedissectionduringradicalprostatectomyforprostatecancer AT taguchikenichi eliminatingmicroscopiclymphnodemetastasisbyperformingpelviclymphnodedissectionduringradicalprostatectomyforprostatecancer AT shimokawamototsugu eliminatingmicroscopiclymphnodemetastasisbyperformingpelviclymphnodedissectionduringradicalprostatectomyforprostatecancer AT nakamuramotonobu eliminatingmicroscopiclymphnodemetastasisbyperformingpelviclymphnodedissectionduringradicalprostatectomyforprostatecancer |